Funder
National Institute of Mental Health
Penn Center for AIDS Research
Penn Mental Health AIDS Research Center
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference54 articles.
1. Guideline On When To Start Antiretroviral Therapy And On Pre-exposure Prophylaxis For HIV. Geneva: World Health Organization. 2015.
http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1
. Accessed 25 Aug 2016.
2. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates and management. A neurobehavioral review. AIDS Rev. 2009;11:103–9.
3. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71–5.
4. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287–300.
5. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional metabolizers, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genom. 2005;15:861–73.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献